Bayer Moves Closer To Astellas With Menopause Drug Filing
Executive Summary
As sales of the Japanese drugmaker’s non-hormonal treatment for menopausal symptoms Veozah finally take off, the German major has filed its potential competitor, elinzanetant, with the US Food and Drug Administration.